The effects of acute oral administration of erythrinian alkaloids, i.e. (؉)-a a-hydroxy-erysotrine, erythravine and (؉)-11a a-hydroxy-erythravine isolated from the flowers of Erythrina mulungu were investigated in two animal models of anxiety in mice-the light-dark transition model (LDTM) and the elevated plus-maze (EPM). In the LDTM, erythravine (3, 10 mg/kg) and (؉)-11a a-hydroxy-erythravine (10 mg/kg) increased the time spent by the animals in the illuminated compartment and (؉)-11a a-hydroxy-erythravine (3 mg/kg) increased the number of transitions between compartments of the LDTM, suggesting an anxiolytic-like effect of these erythrinian alkaloids. Nevertheless, the third alkaloid studied, (؉)-a a-hydroxy-erysotrine, did not change any behavioral response with the range of doses used (3-10 mg/kg). Since the oral administration of the crude extract of E. mulungu (EM) (100-400 mg/kg) did not modify the conventional measures of anxiety in the EPM, this animal model was not chosen to evaluate the anxiolytic properties of the isolated alkaloids. These results suggest that the alkaloids erythravine and (؉)-11a a-hydroxy-erythravine are responsible for the anxiolytic effects of the crude extract of E. mulungu.
In popular medicine, a tincture prepared from the leaves or barks decoction from Erythrina mulungu is used to calm agitation and other nervous system disorders (e.g. insomnia and depression). 1) Commercial preparations of the crude extract of E. mulungu are available in Brazilian and U.S.A. drugstores as a phythomedicine. However, there are a lack of studies demonstrating its safety, efficacy and mechanism of action. In addition, many studies have investigated the potential anxiolytic of the crude extract only, not emphasizing, for instance, which constituents of the E. mulungu alter this emotional state.
For instance, it has been demonstrated that acute and chronic treatments with hydroalcoholic extracts from E. mulungu produce anxiolytic-like effects on a specific subsets of defensive behavior in rats exposed in the elevated T-maze (ETM) and in the light-dark transition model (LDTM). The anti-anxiety effects were similar to that provoked by the wellknown anxiolytic compound diazepam (DZP). 2, 3) Recently 4) we have reported that a new erythrinian alkaloid, (ϩ)-11a-hydroxy-erythravine (OH-Ery), and the two known erythrinian alkaloids, erythravine (Ery) and (ϩ)-ahydroxyerysotrine (Eryso), isolated from E. mulungu impaired the inhibitory avoidance acquisition of the open arms in the ETM, an animal model of anxiety validated for rats 5, 6) and mice. 7) Interestingly, neither crude extract nor erythrinian alkaloids changed locomotion in the arena, suggesting a selective anxiolytic-like effect of these erythrinian compounds. 4) Although the ETM has been validated as an animal model of anxiety for rats 5, 6) and mice 7) it is relevant to investigate the anxiolytic properties of new compounds by using different anxiety tests. In the present study we investigated the effects of the crude extract of E. mulungu (EM) and its alkaloids, the Eryso, Ery and OH-Ery in two widely used tests of anxiety, the light dark transition model (LDTM) 8) and the elevated plus-maze (EPM). 9, 10) 
MATERIAL AND METHODS

Plant Material
The inflorescence was used since the procedure of scraping the bark out of the tree often damages the plant. Inflorescences of Erythrina mulungu MART. were collected at Rifaina, São Paulo State, and exsiccate was deposited at the Department of Vegetal Biotechnology of University of Ribeirão Preto under the code HPM-0032.
Extraction and Isolation The erythrinian alkaloids Eryso (36 mg, 0.03%), Ery (95 mg, 0.08%) and OH-Ery (48 mg, 0.04%) were isolated from the hydroalcoholic crude extract (120 g) as previously reported. 4) Pharmacological Essay. Animals Male Swiss mice (São Paulo State University/UNESP, SP, Brazil), weighing 25-35 g, were housed in groups of 10 per cage (41 cmϫ34 cmϫ16 cm) and maintained under a normal 12-h light cycle (lights on 07:00 h) in a temperature/humidity controlled environment (23Ϯ1°C/55Ϯ5%). Food and water were freely available. All mice were experimentally naive. Experimental procedures were in compliance with the US National Institutes of Health Guide for Care and Use of Laboratory Animals and were approved by the Local Ethical Committee (UNESP-Araraquara/SP, nr 35/2004).
Compound Administration EM and alkaloids were suspended in saline (NaCl 0.9%) and diazepam (DZP) in salineϩ2% Tween 80. Animals were orally treated with EM (100, 200, 400 mg/kg), 2, 3) and with a range of doses (3-10 mg/kg) of each isolated alkaloid, 4) or vehicle (saline). These doses were based on a previous study. 4) A positive control group receiving intraperitoneal injection of diazepam (DZP, 2 mg/kg) was also included in the study. All compounds were administered 30 min before the experimental session.
Apparatus Light-Dark Transition Model (LDTM): The LDTM was a plexiglas box (44.5ϫ37ϫ25 cm) divided by a barrier with a door way (7ϫ7.5 cm) through which mice could cross between two chambers, one made by white walls (27ϫ37ϫ25 cm) and illuminated by a white light (1320 lux, illuminated compartment) and one made by black walls (17ϫ37ϫ25 cm) and illuminated by a red light (35 lux, dark compartment).
Elevated Plus-Maze (EPM): The EPM comprised two open arms (30ϫ5 cm) and two closed arms (30ϫ5ϫ15 cm) that extended from a common central platform (5ϫ5 cm). To avoid falls, the open arms were surrounded by Plexiglas rim 0.25 cm high. The apparatus was constructed from glass (clear walls) and wood (floor) and elevated 38.5 cm above floor level.
Procedure Initially animals were treated with crude extract of EM (0, 100, 200, 400 mg/kg; p.o.) and then individually exposed in the LDTM or EPM. When crude extract of EM produced anxiolytic-like effect the experiment was followed with treatment of each isolated alkaloid (for instance, 3 and 10 mg/kg of Eryso; 3 and 10 mg/kg of Ery; 3 and 10 mg/kg of OH-Ery). At each stage, a positive-control group was added to the study with animals receiving diazepam (2 mg/kg; i.p.), a classical anxiolytic drug.
LDTM: Each animal was placed at the center of the illuminated compartment and, after the first passage to the dark one, the behavior of the animal was video recorded for 5 min to further analysis of the number of transition between compartments and the time spent in the illuminated compartment. Entry into a compartment was recorded when the animal crossed with all four paws the line that separated the two compartments. Statistics All results were initially submitted to Levene's test for homogeneity of variance. Where this test yielded significance, results were log transformed before being submitted to one-way ANOVA, followed by Duncan's Multiple Comparison Test when significant. In all cases a p value Յ0.05 was considered significant. Figure 1 Fig. 1D ). Although one-way ANOVA had revealed significant effect of Eryso, post hoc analysis showed that only diazepam treated animals spent more time in the illuminated compartment. This effect of diazepam was also present in A, C and D.
RESULTS
Light Dark Transition Model
As shown in Fig. 2 , ANOVA did not reveal significant differences of treatments on the number of transitions between both compartments of the LDTM for EM [F(4,43)ϭ1.34; pϭ0.26; Fig. 2A ], Eryso [F(3,49)ϭ1.19; pϭ0.31; Fig. 2B ], Ery [F(3,39)ϭ1.13; pϭ0.34; Fig. 2C ]. However, one-way ANOVA revealed effect of OH-Ery [F(3,38)ϭ3.36; pϽ0.05; Fig. 2D ]. As shown in Fig. 2D , the dose of 3 mg/kg of OHEry increased the number of transitions between both compartments (pՅ0.05). 
DISCUSSION
This study demonstrated that acute p.o. treatment with EM and the alkaloids, erythravine and (ϩ)-11a-hydroxy-erythravine produced anxiolytic effects in a classical animal model of anxiety, the LDTM. Similarly to the reference drug, the benzodiazepine DZP, EM (100, 200 mg/kg), erythravine (3, 10 mg/kg), and (ϩ)-11a-hydroxy-erythravine (10 mg/kg) increased the time spent by the animals in the illuminated compartment. In addition, (ϩ)-11a-hydroxy-erythravine (3 mg/kg) increased the number of transitions between compartments of the LDTM. This seems to be a selective anxiolytic-like effect since we have recently demonstrated that (ϩ)-11a-hydroxy-erythravine did not alter the locomotor activity in the arena test in mice. 4) Unexpectedly, the present study failed to demonstrate anxiolytic effects of the alkaloid (ϩ)-a-hydroxy-erysotrine in the LDTM. Such failure contrasts with recent results, 4) in which this erythrinian alkaloid (3, 10 mg/kg) impaired inhibitory avoidance acquisition in the elevated T-maze, an anxiolytic-like effect. Thus it is not clear why (ϩ)-a-hydroxy-erysotrine did not alter anxiety in the LDTM. Further studies involving the use of higher doses of (ϩ)-a-hydroxyerysotrine could contribute to compare its potency to that of other erythrinian alkaloids (e.g. erythravine and (ϩ)-11a-hydroxy-erythravine) in attenuating anxiety in the LDTM.
Taken together, present results with LDTM corroborate previous studies that have reported anxiolytic effects produced by acute (100 mg/kg) and chronic (50 mg/kg) treatment with EM p.o. in rats in the LDTM. 2, 3) In addition, present results also support a recent study using the elevated Tmaze (ETM) as an animal model of anxiety in mice. 4) In that study we have demonstrated that the alkaloids present in the hydroalcoholic extract of E. mulungu are responsible, at least in part, for its anxiolytic effects recorded in the ETM. Briefly, acute p.o. treatment with erythravine (3, 10 mg/kg), (ϩ)-11a-hydroxy-erythravine (3, 10 mg/kg) and (ϩ)-a-hydroxyerysotrine (3, 10 mg/kg) impaired the inhibitory avoidance acquisition from the open arms of the ETM for mice, suggesting an anxiolytic effect of these erythrinian compounds. 4) In the present study EM failed to alter anxiety indices in the EPM in mice. This lack of effects has been previously demonstrated. drugs in anxiety disorders (e.g. buspirone, antidepressants). 12) For instance, serotonin (5-HT) reuptake blockers and 5-HT 1A receptor agonists produce anxiolytic and anxiogenic effects in the EPM. 8) There are also reports showing that these compounds fail to alter anxiety in the rodent EPM. 8) Thus, the failure of effects of E. mulungu on anxiety in the EPM does not necessarily exclude its potential as an anxiolytic natural product.
The underlying mechanisms involved in the anxiolytic effects of the erythrinian alkaloids was not the scope of the present study and remain to be determined. Hypothetically, erythrinian alkaloids may act at GABA/benzodiazepine receptor complex. It has been reported that the alkaloids present in several species of Erythrina affect GABAergic neurotransmission. 15) However, since GABA/benzodiazepine receptor complex agonists usually produce motoric disruption (i.e. moderate doses increase locomotion and high doses impair locomotion) and crude extract of EM as well as its isolated alkaloids failed to alter locomotor behavior, it is unlikely that the anti-anxiety effects provoked with E. mulungu (mainly with higher doses) involve GABA/benzodiazepine complex mechanisms. It has been demonstrated that the crude extract of Erythrina vespertilio inhibited platelet 5-HT release. 13) Platelets have been used as a useful model for studying Ca 2ϩ -dependent 5-HT release, 13) the main action of serotonin at 5-HT 3 receptors. In addition, it has been demonstrated the dihydro-b-erythroidine, an erythrinian alkaloid, antagonizes the effects of 5-HT in eliciting currents related to 5-HT 3 receptor stimulation. 14) In view of this evidence, it is tempting to speculate that the anxiolytic profile obtained in the present study can be attributed to an antagonist action of erythrinian alkaloids at 5HT 3 receptors. Although attractive, such hypothesis remain to be empirically tested e.g. with in vitro and in vivo methods.
Corroborating our previous study, 4) the present results strongly suggest that the erythrinian alkaloids isolated from E. mulungu are markedly involved in the anxiolytic effects of the crude extract, and support the popular use of a tincture prepared from the leaves or barks decoction from E. mulungu as an anxiolytic medicine.
